{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:20:21Z","timestamp":1790007621287,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s11899-009-0037-y","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T08:31:00Z","timestamp":1262853060000},"page":"15-21","source":"Crossref","is-referenced-by-count":5,"title":["New Drugs for the Treatment of Myelofibrosis"],"prefix":"10.1007","volume":"5","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,8]]},"reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092\u20131097.","journal-title":"Blood"},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, et al.: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007, 109:68\u201376.","journal-title":"Cancer"},{"key":"37_CR3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, et al.: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105:973\u2013977.","journal-title":"Blood"},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"\u2022 Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2985\u20132901. This key reference for the prognosis of patients with primary myelofibrosis is the most definitive prognostic paper to date, drawing on experience with over 1000 patients.","journal-title":"Blood"},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(97)90022-9","volume":"11","author":"JT Reilly","year":"1997","unstructured":"Reilly JT: Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997, 11:233\u2013242.","journal-title":"Blood Rev"},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4065\/78.10.1223","volume":"78","author":"CA Koch","year":"2003","unstructured":"Koch CA, Li CY, Mesa RA, Tefferi A: Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003, 78:1223\u20131233.","journal-title":"Mayo Clin Proc"},{"key":"37_CR7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01725198","volume":"67","author":"BR Anger","year":"1989","unstructured":"Anger BR, Seifried E, Scheppach J, Heimpel H: Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989, 67:818\u2013825.","journal-title":"Klin Wochenschr"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","volume":"102","author":"HJ Deeg","year":"2003","unstructured":"Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912\u20133918.","journal-title":"Blood"},{"key":"37_CR9","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","volume":"1\u20135","author":"D Rondelli","year":"2005","unstructured":"Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 1\u20135:4115\u20134119.","journal-title":"Blood"},{"key":"37_CR10","doi-asserted-by":"crossref","unstructured":"Kroger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2009 Oct 7 (Epub ahead of print).","DOI":"10.1182\/blood-2009-07-234880"},{"key":"37_CR11","first-page":"616","volume":"83","author":"JN Rodriguez","year":"1998","unstructured":"Rodriguez JN, Martino ML, Dieguez JC, Prados D: rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998, 83:616\u2013621.","journal-title":"Haematologica"},{"key":"37_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4","volume":"49","author":"EC Besa","year":"1982","unstructured":"Besa EC, Nowell PC, Geller NL, Gardner FH: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982, 49:308\u2013313.","journal-title":"Cancer"},{"key":"37_CR13","first-page":"595","volume":"85","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, Hernandez-Boluda JC, Alvarez A, et al.: Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000, 85:595\u2013599.","journal-title":"Haematologica"},{"key":"37_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<239::AID-AJH5>3.0.CO;2-Z","volume":"53","author":"V Levy","year":"1996","unstructured":"Levy V, Bourgarit A, Delmer A, et al.: Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996, 53:239\u2013241.","journal-title":"Am J Hematol"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988, 41:375\u2013381.","journal-title":"Eur J Haematol"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T, et al.: Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 116:576\u2013581.","journal-title":"Br J Haematol"},{"key":"37_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2004.00370.x","volume":"74","author":"LN Faoro","year":"2005","unstructured":"Faoro LN, Tefferi A, Mesa RA: Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74:117\u2013120.","journal-title":"Eur J Haematol"},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","volume":"96","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Elliott MA: Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter]. Blood 2000, 96:4007.","journal-title":"Blood"},{"key":"37_CR19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.03072.x","volume":"115","author":"L Canepa","year":"2001","unstructured":"Canepa L, Ballerini F, Varaldo R, et al.: Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001, 115:313\u2013315.","journal-title":"Br J Haematol"},{"key":"37_CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","volume":"114","author":"G Barosi","year":"2001","unstructured":"Barosi G, Grossi A, Comotti B, et al.: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114:78\u201383.","journal-title":"Br J Haematol"},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","volume":"19","author":"M Merup","year":"2002","unstructured":"Merup M, Kutti J, Birgergard G, et al.: Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002, 19:79\u201386.","journal-title":"Med Oncol"},{"key":"37_CR22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","volume":"117","author":"MA Elliott","year":"2002","unstructured":"Elliott MA, Mesa RA, Li CY, et al.: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 117:288\u2013296.","journal-title":"Br J Haematol"},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534\u20132541.","journal-title":"Blood"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158\u20131164.","journal-title":"Blood"},{"key":"37_CR25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549\u2013557.","journal-title":"N Engl J Med"},{"key":"37_CR26","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Lasho TL, Mesa RA, et al.: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007, 21:1827\u20131828.","journal-title":"Leukemia"},{"key":"37_CR27","doi-asserted-by":"crossref","unstructured":"Mesa RA, Yao X, Cripe LD, et al.: Lenalidomide and prednisone for primary and post polycythemia vera\/essential thrombocythemia myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1753.","DOI":"10.1182\/blood.V112.11.1753.1753"},{"key":"37_CR28","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Kantarjian HM, Thomas DA, et al.: Combined therapy with lenalidomide and prednisone renders durable clinical, histopathological, and molecular responses in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 662.","DOI":"10.1182\/blood.V112.11.662.662"},{"key":"37_CR29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054\u20131061.","journal-title":"Lancet"},{"key":"37_CR30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779\u20131790.","journal-title":"N Engl J Med"},{"key":"37_CR31","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144\u20131148.","journal-title":"Nature"},{"key":"37_CR32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell 2005, 7:387\u2013397.","journal-title":"Cancer Cell"},{"key":"37_CR33","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, et al.: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472\u20133476.","journal-title":"Blood"},{"key":"37_CR34","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della Valle V, et al.: Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289\u20132301.","journal-title":"N Engl J Med"},{"key":"37_CR35","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","volume":"111","author":"A Pardanani","year":"2008","unstructured":"Pardanani A, Fridley BL, Lasho TL, et al.: Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008, 111:2785\u20132789.","journal-title":"Blood"},{"key":"37_CR36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, et al.: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41:446\u2013449.","journal-title":"Nat Genet"},{"key":"37_CR37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, Harutyunyan A, Jager R, et al.: A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41:450\u2013454.","journal-title":"Nat Genet"},{"key":"37_CR38","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","volume":"9","author":"GW Muller","year":"1999","unstructured":"Muller GW, Chen R, Huang SY, et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9:1625\u20131630.","journal-title":"Bioorg Med Chem Lett"},{"key":"37_CR39","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, Fields P, Bartlett JB, et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22:3269\u20133276.","journal-title":"J Clin Oncol"},{"key":"37_CR40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/leu.2008.136","volume":"23","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Verstovsek S, Rivera C, et al.: 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009, 23:180\u2013182.","journal-title":"Leukemia"},{"key":"37_CR41","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","volume":"22","author":"A Quint\u00e1s-Cardama","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Tong W, Kantarjian H, et al.: A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis. Leukemia 2008, 22:965\u2013970.","journal-title":"Leukemia"},{"key":"37_CR42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223\u2013232.","journal-title":"Lancet Oncol"},{"key":"37_CR43","doi-asserted-by":"crossref","unstructured":"\u2022 Verstovsek S, Kantarjian HM, Pardanani AD, et al.: The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (post PV\/ETMF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1762. INCB018424 is the class-leading JAK2 inhibitor for myelofibrosis, with activity for splenomegaly and MF-associated symptoms.","DOI":"10.1200\/jco.2008.26.15_suppl.7004"},{"key":"37_CR44","doi-asserted-by":"crossref","unstructured":"Mesa RA, Verstovsek S, Kantarjian HM, et al.: INCB018424, a selective JAK1\/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1760.","DOI":"10.1182\/blood.V112.11.1760.1760"},{"key":"37_CR45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D, et al.: The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009, 33:1199\u20131203.","journal-title":"Leuk Res"},{"key":"37_CR46","doi-asserted-by":"crossref","unstructured":"\u2022 Pardanani AD, Gotlib J, Jamieson C, et al.: A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 97. TG101348 is a promising selective JAK2 inhibitor with activity in MF.","DOI":"10.1182\/blood.V112.11.97.97"},{"key":"37_CR47","doi-asserted-by":"crossref","unstructured":"\u2022 Shah NP, Olszynski P, Sokol L, et al.: A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 98. This JAK2 inhibitor ceased development because of neurologic toxicity.","DOI":"10.1182\/blood.V112.11.98.98"},{"key":"37_CR48","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Tefferi A, Kornblau S, et al.: Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3543.","DOI":"10.1182\/blood.V110.11.3543.3543"},{"key":"37_CR49","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Dellacasa CM, Salmoiraghi S, et al.: A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 100.","DOI":"10.1182\/blood.V112.11.100.100"},{"key":"37_CR50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","volume":"127","author":"F Cervantes","year":"2004","unstructured":"Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al.: Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004, 127:399\u2013403.","journal-title":"Br J Haematol"},{"key":"37_CR51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0609.1984.tb00724.x","volume":"33","author":"A Manoharan","year":"1984","unstructured":"Manoharan A, Pitney WR: Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984, 33:453\u2013459.","journal-title":"Scand J Haematol"},{"key":"37_CR52","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","volume":"89","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD: Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65\u00a0years of age. The French Polycythemia Study Group. Blood 1997, 89:2319\u20132327.","journal-title":"Blood"},{"key":"37_CR53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1365-2141.1997.3843198.x","volume":"99","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997, 99:352\u2013357.","journal-title":"Br J Haematol"},{"key":"37_CR54","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","volume":"43","author":"G Barosi","year":"2002","unstructured":"Barosi G, Elliot MA, Canepa L, et al.: Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002, 43:2301\u20132307.","journal-title":"Leuk Lymphoma"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0037-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0037-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0037-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T13:43:44Z","timestamp":1590500624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0037-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0037-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}